Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

NIH GIST Risk (Miettinen)

The NIH (Fletcher) Consensus Criteria stratifies the risk of aggressive behavior and metastasis in Gastrointestinal Stromal Tumors (GIST) based on tumor size and mitotic index.

Evidence-based context for fast calculator use

Purpose:
NIH GIST risk classification stratifies gastrointestinal stromal tumors by size and mitotic count to guide adjuvant imatinib therapy decisions.
Population:
patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model
Factors:
Tumor Size, Mitotic Count
Reference:
Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33(5):459-465.
HomeNIH GIST Risk (Miettinen)
Pin your most used calculators here by clicking the star in the dropdown.

NIH GIST Risk (Miettinen)

Clinical Context & Background

The NIH (Fletcher) Consensus Criteria stratifies the risk of aggressive behavior and metastasis in Gastrointestinal Stromal Tumors (GIST) based on tumor size and mitotic index. Note: It does not account for tumor location (see AFIP-Miettinen criteria for location-specific risk).
Primary Source EvidenceFletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33(5):459-465.
Formula Logic
Risk matrix based on Size (cm) and Mitoses (/50 HPF).

Reference Data

Risk GroupTumor SizeMitotic Count (/50 HPF)
Very Low Risk< 2 cm< 5
Low Risk2 - 5 cm< 5
Intermediate Risk< 5 cm6 - 10
Intermediate Risk5 - 10 cm< 5
High Risk> 5 cm> 5
High Risk> 10 cmAny count
High RiskAny size> 10

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use NIH GIST Risk (Miettinen) when nIH GIST risk classification stratifies gastrointestinal stromal tumors by size and mitotic count to guide adjuvant imatinib therapy decisions.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Very Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm primary site, histology, stage, surgery status, systemic-treatment timing, and disease-specific guideline before applying the result.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not transfer thresholds across colorectal, GIST, gastric, appendiceal, and other peritoneal malignancies.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model

How to apply this result

For a representative case, verify Tumor Size, Mitotic Count, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

GI, GIST & Peritoneal hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

Modified Glasgow Prognostic Score (mGPS)Fong Clinical Risk Score (CRS)Peritoneal Carcinomatosis Index (PCI)

Frequently Asked Questions

When should NIH GIST Risk (Miettinen) be used?

Use it for patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model when all required inputs and the intended clinical setting are confirmed.

Can NIH GIST Risk (Miettinen) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.